Evidence map›Paper›PMID 42840581›Full record

ReviewFrontiers in immunology2026

Molecular mimicry revisited: novel perspectives on autoimmune disease initiation and progression.

Urs Christen, Edith Hintermann

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Urs ChristenInstitute for Pharmacology and Toxicology, Goethe University Frankfurt, Frankfurt am Main, Germany.
Edith HintermannInstitute for Pharmacology and Toxicology, Goethe University Frankfurt, Frankfurt am Main, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular mimicry has long been implicated as one possible mechanism linking pathogen infection to autoimmunity, yet firm proof of its contribution to disease initiation and/or progression remains incompletely defined. In this review, we revisit the concept of molecular mimicry in light of recent advances in immunology, structural biology, and systems medicine. Beyond classical sequence homology, emerging evidence highlights the importance of structural and conformational epitope similarity, post-translational modifications, and context-dependent antigen presentation in shaping cross-reactive immune responses. We discuss how these factors influence the activation of autoreactive T and B cells, the breakdown of immune tolerance, and the establishment of chronic autoimmune disease. We further reevaluate the body of evidence for molecular mimicry as inducer and/or accelerator of specific autoimmune diseases ranging from mere association to proven causative relationship. Thereby, we further examine novel experimental approaches that have refined the identification of mimicry candidates and improved our understanding of their pathogenic relevance. By integrating classical paradigms with contemporary findings, this review provides a detailed outline for understanding molecular mimicry as a dynamic and multi-layered contributor to autoimmune disease.

Indexed as

Autoimmune DiseasesMolecular MimicryAnimalsAutoimmunityB-LymphocytesDisease ProgressionHumansautoimmune diseaseepitopemolecular identitymolecular similaritypathogen infection

Identifiers

PMID42840581
PMCPMC13639941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.